PARSIPPANY, N.J. & SAN DIEGO--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority (BARDA) to support the development of CARBAVANCE® (meropenem/RPX7009). CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant (MDR) gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).
Help employers find you! Check out all the jobs and post your resume.
